| Primary |
| Idiopathic Thrombocytopenic Purpura |
45.6% |
| Immune Thrombocytopenic Purpura |
26.3% |
| Prophylaxis |
7.5% |
| Product Used For Unknown Indication |
6.7% |
| Thrombocytopenia |
2.9% |
| Hypertension |
1.9% |
| Autoimmune Thrombocytopenia |
1.8% |
| Hepatitis C |
1.0% |
| Infection Prophylaxis |
1.0% |
| Constipation |
0.7% |
| Viith Nerve Paralysis |
0.7% |
| Osteoporosis Prophylaxis |
0.6% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.6% |
| Cardiac Failure |
0.5% |
| Gastric Ulcer |
0.5% |
| Osteoporosis |
0.5% |
| Platelet Count Decreased |
0.4% |
| Vasculitis |
0.4% |
| Abdominal Pain Upper |
0.3% |
| Bronchopulmonary Aspergillosis |
0.3% |
|
| Pulmonary Embolism |
12.3% |
| Death |
8.9% |
| Cerebral Infarction |
8.2% |
| Platelet Count Decreased |
8.2% |
| Pyrexia |
7.5% |
| Myelofibrosis |
5.5% |
| Vomiting |
5.5% |
| Malaise |
4.1% |
| Renal Impairment |
4.1% |
| Thrombocytopenia |
4.1% |
| White Blood Cell Count Increased |
4.1% |
| Cerebral Haemorrhage |
3.4% |
| Deep Vein Thrombosis |
3.4% |
| Myelodysplastic Syndrome |
3.4% |
| Toxic Skin Eruption |
3.4% |
| Arterial Thrombosis |
2.7% |
| Liver Disorder |
2.7% |
| Off Label Use |
2.7% |
| Thrombocytosis |
2.7% |
| Visual Impairment |
2.7% |
|
| Secondary |
| Idiopathic Thrombocytopenic Purpura |
42.6% |
| Immune Thrombocytopenic Purpura |
32.7% |
| Prophylaxis |
11.0% |
| Product Used For Unknown Indication |
5.1% |
| Vasculitis |
1.3% |
| Hypertension |
0.8% |
| Constipation |
0.7% |
| Infection Prophylaxis |
0.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.7% |
| Insomnia |
0.6% |
| Osteoporosis Prophylaxis |
0.5% |
| Gastritis Prophylaxis |
0.4% |
| Osteoporosis |
0.4% |
| Anaemia Prophylaxis |
0.4% |
| Urinary Tract Infection |
0.4% |
| Viith Nerve Paralysis |
0.4% |
| Antifungal Prophylaxis |
0.3% |
| Cerebral Infarction |
0.3% |
| Chronic Hepatitis C |
0.3% |
| Convulsion |
0.3% |
|
| Cerebral Infarction |
10.9% |
| Pyrexia |
7.2% |
| Palpitations |
6.5% |
| Liver Disorder |
5.8% |
| Pulmonary Hypertension |
5.8% |
| Renal Impairment |
5.8% |
| White Blood Cell Count Increased |
5.8% |
| Myocardial Ischaemia |
5.1% |
| Systemic Inflammatory Response Syndrome |
5.1% |
| Vomiting |
5.1% |
| Agranulocytosis |
4.3% |
| Diabetes Mellitus |
4.3% |
| Myelodysplastic Syndrome |
4.3% |
| Sepsis |
4.3% |
| Interstitial Lung Disease |
3.6% |
| Pulmonary Embolism |
3.6% |
| Pulmonary Hypertensive Crisis |
3.6% |
| Cerebellar Infarction |
2.9% |
| Malaise |
2.9% |
| Mobility Decreased |
2.9% |
|
| Concomitant |
| Hepatitis C |
17.7% |
| Idiopathic Thrombocytopenic Purpura |
11.6% |
| Immune Thrombocytopenic Purpura |
9.2% |
| Prophylaxis |
8.0% |
| Chronic Hepatitis C |
7.3% |
| Product Used For Unknown Indication |
6.7% |
| Hypertension |
4.9% |
| Osteoporosis |
4.3% |
| Thrombocytopenia |
4.0% |
| Gastritis |
3.7% |
| Gastrointestinal Haemorrhage |
3.1% |
| Postoperative Care |
2.8% |
| Pruritus |
2.8% |
| Uterine Leiomyoma |
2.8% |
| Hepatic Cirrhosis |
2.4% |
| Anaemia |
2.1% |
| Diabetes Mellitus |
2.1% |
| Neutropenia |
1.8% |
| Liver Transplant |
1.5% |
| Cardiac Failure Congestive |
1.2% |
|
| Drug Ineffective |
16.3% |
| Platelet Count Decreased |
11.6% |
| Hepatic Encephalopathy |
7.0% |
| Myelodysplastic Syndrome |
7.0% |
| Arterial Occlusive Disease |
4.7% |
| General Physical Health Deterioration |
4.7% |
| Leukopenia |
4.7% |
| Malaise |
4.7% |
| Pancytopenia |
4.7% |
| Pyrexia |
4.7% |
| Rash |
4.7% |
| Renal Disorder |
4.7% |
| Thrombocytopenia |
4.7% |
| Ascites |
2.3% |
| Bacterial Sepsis |
2.3% |
| Death |
2.3% |
| Diabetes Mellitus |
2.3% |
| Hyperglycaemia |
2.3% |
| Hypoglycaemia |
2.3% |
| Infection |
2.3% |
|
